TWI863962B - 癌症治療 - Google Patents

癌症治療 Download PDF

Info

Publication number
TWI863962B
TWI863962B TW109104389A TW109104389A TWI863962B TW I863962 B TWI863962 B TW I863962B TW 109104389 A TW109104389 A TW 109104389A TW 109104389 A TW109104389 A TW 109104389A TW I863962 B TWI863962 B TW I863962B
Authority
TW
Taiwan
Prior art keywords
erdafitinib
cancer
serum phosphate
treatment
specifically
Prior art date
Application number
TW109104389A
Other languages
English (en)
Chinese (zh)
Other versions
TW202045173A (zh
Inventor
安 奧哈根
彼得 德波雷
安嘉莉 阿瓦達尼
Original Assignee
比利時商健生藥品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 比利時商健生藥品公司 filed Critical 比利時商健生藥品公司
Publication of TW202045173A publication Critical patent/TW202045173A/zh
Application granted granted Critical
Publication of TWI863962B publication Critical patent/TWI863962B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW109104389A 2019-02-12 2020-02-12 癌症治療 TWI863962B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19156806 2019-02-12
EP19156806.2 2019-02-12
EP19176575 2019-05-24
EP19176575.9 2019-05-24

Publications (2)

Publication Number Publication Date
TW202045173A TW202045173A (zh) 2020-12-16
TWI863962B true TWI863962B (zh) 2024-12-01

Family

ID=69467563

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109104389A TWI863962B (zh) 2019-02-12 2020-02-12 癌症治療

Country Status (16)

Country Link
US (1) US20220168298A1 (enExample)
EP (1) EP3923942A1 (enExample)
JP (1) JP2022521173A (enExample)
KR (1) KR20210126654A (enExample)
CN (1) CN113423402A (enExample)
AU (1) AU2020223467B2 (enExample)
BR (1) BR112021015686A2 (enExample)
CA (1) CA3126959A1 (enExample)
IL (1) IL285466A (enExample)
JO (1) JOP20210216A1 (enExample)
MA (1) MA54932A (enExample)
MX (1) MX2021009670A (enExample)
PH (1) PH12021551949A1 (enExample)
SG (1) SG11202107850VA (enExample)
TW (1) TWI863962B (enExample)
WO (1) WO2020165181A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117083283A (zh) * 2020-12-11 2023-11-17 医睿世康药业研发公司 用于癌症治疗的联合疗法
JP2023553533A (ja) * 2020-12-11 2023-12-21 エラスカ，インク． 癌の処置のための併用療法
CN112957368A (zh) * 2021-04-02 2021-06-15 南昌大学 一种司维拉姆的新用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201839399A (zh) * 2017-02-06 2018-11-01 比利時商健生藥品公司 癌症治療

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113957146A (zh) * 2014-09-26 2022-01-21 詹森药业有限公司 使用fgfr突变基因组鉴定将对用fgfr抑制剂进行治疗有反应的癌症患者
JOP20200201A1 (ar) * 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
WO2017070708A1 (en) * 2015-10-23 2017-04-27 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
JOP20190190A1 (ar) * 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201839399A (zh) * 2017-02-06 2018-11-01 比利時商健生藥品公司 癌症治療

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Joaquim Bellmunt et al., "Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens", J Clin Oncol, 28, APRIL 10 2010, 1850-1855. *

Also Published As

Publication number Publication date
SG11202107850VA (en) 2021-08-30
TW202045173A (zh) 2020-12-16
US20220168298A1 (en) 2022-06-02
AU2020223467A1 (en) 2021-08-05
JOP20210216A1 (ar) 2023-01-30
CA3126959A1 (en) 2020-08-20
EP3923942A1 (en) 2021-12-22
PH12021551949A1 (en) 2022-07-18
KR20210126654A (ko) 2021-10-20
AU2020223467B2 (en) 2025-12-04
MA54932A (fr) 2021-12-22
BR112021015686A2 (pt) 2021-10-26
CN113423402A (zh) 2021-09-21
IL285466A (en) 2021-09-30
MX2021009670A (es) 2021-09-08
WO2020165181A1 (en) 2020-08-20
JP2022521173A (ja) 2022-04-06

Similar Documents

Publication Publication Date Title
TWI874925B (zh) 癌症治療
TWI798199B (zh) 癌症治療
EP4548935A2 (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
TWI863962B (zh) 癌症治療
JP2025156297A (ja) 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤
HK40103983A (en) Cancer treatment
HK40013982A (en) Cancer treatment
HK40064232A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
HK40018978B (en) Cancer treatment
HK40018978A (en) Cancer treatment